What are the treatment options for hidradenitis suppurativa?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment Options for Hidradenitis Suppurativa

For hidradenitis suppurativa (HS), treatment should be selected based on disease severity, with topical therapies and oral antibiotics for mild disease, combination antibiotics for moderate disease, and biologics like adalimumab for severe disease. 1

Treatment Based on Disease Severity

Mild Disease (Hurley Stage I)

  • First-line options:
    • Topical clindamycin 1% solution - reduces pustules and improves patient self-assessment 1
    • Antiseptic washes as adjunctive therapy 1
    • Resorcinol 15% cream - reduces pain and duration of abscesses (monitor for irritant dermatitis) 1, 2
    • Oral tetracyclines (doxycycline 100mg twice daily) for at least 12 weeks 1
  • For persistent lesions:
    • Localized surgical intervention 1
    • Intralesional corticosteroid injections 2
    • LAight therapy (combination of intense pulsed light with radiofrequency) - shown to significantly enhance efficacy when combined with topical clindamycin 3

Moderate Disease (Hurley Stage II)

  • First-line therapy:
    • Combination of clindamycin and rifampin for 10-12 weeks 1, 4
  • Second-line therapy:
    • Adalimumab if inadequate response to antibiotics 1, 5
    • Dosing: 160 mg initially, 80 mg at week 2, then 40 mg weekly starting at week 4 1, 5

Severe Disease (Hurley Stage III)

  • First-line therapy:
    • Adalimumab (FDA-approved) 1, 5
    • Dosing for adults: 160 mg on day 1,80 mg on day 15, then 40 mg weekly or 80 mg every other week starting on day 29 5
  • Surgical options:
    • Extensive surgical excision with reconstruction using grafts or flaps (lower recurrence rates than primary closure) 1
    • CO₂ laser excision for fibrotic sinus tracts 1

Adalimumab (Humira) - The Only FDA-Approved Biologic for HS

  • Dosing for adults:

    • Day 1: 160 mg (given in one day or split over two consecutive days)
    • Day 15: 80 mg
    • Day 29 and subsequent doses: 40 mg weekly or 80 mg every other week 5
  • Dosing for adolescents (12 years and older):

    • For 30-60 kg: Day 1: 80 mg; Day 8 and subsequent doses: 40 mg every other week
    • For ≥60 kg: Day 1: 160 mg; Day 15: 80 mg; Day 29 and subsequent doses: 40 mg weekly or 80 mg every other week 5
  • Important safety considerations:

    • Monitor for serious infections, including tuberculosis
    • Screen for latent TB before initiating therapy
    • Risk of malignancy, particularly lymphoma 1, 5

Other Biologic Options

  • Infliximab: 5mg/kg every 8 weeks can be considered if adalimumab is ineffective 1
  • Anakinra: May be considered in refractory cases 6

Special Populations

  • Pregnant patients:

    • Cephalexin or azithromycin are safer options for systemic antibiotics
    • Clindamycin monotherapy may be considered 1
  • Pediatric patients:

    • Doxycycline for patients ≥8 years old
    • Adalimumab approved for patients 12 years and older 1, 5
  • Breastfeeding patients:

    • Avoid doxycycline or limit to 3 weeks without repeating courses 1

Wound Care

  • Choose dressings based on:

    • Drainage amount
    • Location
    • Periwound skin condition
    • Cost and patient preference 1
  • Consider negative-pressure therapy for large open wounds (1-4 weeks) followed by delayed reconstruction 1

Common Pitfalls and Caveats

  1. Misdiagnosis: HS is often misdiagnosed as simple boils or abscesses, leading to inappropriate treatment 6

  2. Delayed treatment: Early intervention is crucial to prevent disease progression and complications 7

  3. Inadequate duration of antibiotic therapy: Oral tetracyclines should be administered for at least 12 weeks 1

  4. Monotherapy limitations: A comprehensive approach combining medical and surgical interventions is often necessary, as fibrotic lesions generally do not respond to medical treatment alone 6

  5. Monitoring complications: Watch for:

    • C. difficile colitis with clindamycin use
    • Serious infections with biologics
    • Local skin irritation with topical treatments 1
  6. Treatment resistance: HS often requires long-term maintenance therapy and may need adjustment of treatment strategies over time 4

References

Guideline

Hidradenitis Suppurativa Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

[Topical and novel device-based therapies for mild hidradenitis suppurativa].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2021

Research

[Antibiotic treatment of hidradenitis suppurativa].

Annales de dermatologie et de venereologie, 2012

Research

Treatments for hidradenitis suppurativa.

Clinics in dermatology, 2017

Research

Management of patients with hidradenitis suppurativa.

Actas dermo-sifiliograficas, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.